AbbVie Lupin $977M+ Partnership to Develop Blood Cancer Inhibitors
AbbVie will partner with Lupin, an Indian Biopharma company located in
Mumbai, to develop and commercialize Lupin's Mucosa-Associated
Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) inhibitors as
novel therapies for various blood cancers, in a close to $1 billion
collaboration. Under the pact, Lupin has received exclusive […]
The post AbbVie Lupin $977M+ Partnership to Develop Blood Cancer
Inhibitors appeared first on BioTecNika .
https://www.biotecnika.org/2018/12/abbvie-lupin-977m-partnership-to-develop-blood-cancer-inhibitors/
Biotech News
No comments:
Post a Comment